Gastroparesis Medications

Gastroparesis medications fall into two groups. Prokinetics, such as metoclopramide and erythromycin, help the stomach muscles contract so food empties faster. Antiemetics, such as ondansetron and prochlorperazine, calm the nausea and vomiting that gastroparesis can cause. Medication is one part of a wider plan that also includes diet and, when diabetes is involved, blood sugar control.

What gastroparesis medications are available?

Two jobs guide the choice. Some drugs, called prokinetics, speed up a stomach that empties slowly. Others, called antiemetics, do not change emptying but ease the nausea and vomiting. According to the National Institute of Diabetes and Digestive and Kidney Diseases, medication is usually added when changes to eating habits are not enough on their own. One drug, metoclopramide, is the only medication the Food and Drug Administration has approved specifically for gastroparesis; the others are prescribed off-label, meaning for a use the official label does not list. Our guide to gastroparesis treatment shows where medication fits in the wider plan, and our page on natural and home remedies for gastroparesis covers the non-drug options.

What are prokinetics?

Prokinetics are drugs that strengthen and coordinate the contractions that move food out of the stomach. Because the central problem in gastroparesis is a stomach that empties too slowly, prokinetics target the condition directly rather than only its symptoms. They tend to work best when taken before meals, so the stomach is primed to empty as food arrives. Each one carries trade-offs, which is why a doctor matches the drug to the person and reviews it over time. The three used most often are metoclopramide, erythromycin, and domperidone.

Metoclopramide

Metoclopramide is the first-choice prokinetic and the only one the Food and Drug Administration has approved for gastroparesis. It comes as a tablet, a liquid, an injection, and, since 2020, a nasal spray sold as Gimoti, which the agency approved for adults with acute and recurrent diabetic gastroparesis. The drug speeds emptying and can also ease nausea.

Its main drawback is a serious one. Metoclopramide carries the agency's strongest safety alert, a boxed warning, because it can cause tardive dyskinesia, a movement disorder of the face, tongue, or limbs that may become permanent. The risk grows with higher doses and longer use, so the Food and Drug Administration advises against taking any form of metoclopramide for more than twelve weeks unless the benefit clearly outweighs the risk. Anyone who notices involuntary movements should contact a doctor promptly.

Erythromycin

Erythromycin is an antibiotic that, at low doses, also acts on a natural signal called motilin to trigger stronger stomach contractions. It can speed emptying quickly, which makes it useful in the short term, and a hospital may give it through a vein when symptoms are severe. Its usefulness fades with time. Within about four weeks the stomach's motilin receptors become less responsive, an effect called tachyphylaxis, so the drug often loses its strength when taken for long stretches. Erythromycin can also affect heart rhythm and, as an antibiotic, encourages resistant bacteria with extended use. For these reasons it is generally reserved for short courses rather than ongoing therapy.

Domperidone

Domperidone is a prokinetic used widely in other countries, but it is not approved in the United States. It speeds emptying and eases nausea with fewer effects on the brain than metoclopramide, yet it carries its own risk: it can disturb heart rhythm and, rarely, lead to serious cardiac events.

For years, United States patients aged twelve and older who had not improved on standard treatment were able to obtain it only through a special Food and Drug Administration program called expanded access. That route has narrowed sharply. The program's supplier stopped making the drug, and the Food and Drug Administration has said domperidone would no longer be distributed for expanded access once the remaining supply ran out, around September 2025. Our page on domperidone and gastroparesis covers its United States access and safety in full, and anyone considering it should discuss current options with a doctor.

What medications help with nausea and vomiting?

When the hardest symptom is nausea or vomiting rather than slow emptying, doctors often add an antiemetic. These drugs do not move food along, but they make daily life more bearable while other treatments work. Common choices include ondansetron, prochlorperazine, and promethazine. They are usually used together with a prokinetic and diet changes rather than on their own. As with any medication, each has side effects to weigh, so the choice depends on a person's other conditions and the medicines they already take.

How long can gastroparesis medications be used?

Duration is a recurring theme with these drugs. The boxed warning limits metoclopramide to about twelve weeks, erythromycin tends to lose its effect after roughly a month, and domperidone access has all but ended. This is why doctors review medication regularly and treat it as one tool rather than a standalone fix. New options are slow to arrive. Metoclopramide remains the only medication approved specifically for gastroparesis, and in 2024 the Food and Drug Administration declined an application for a proposed new drug, tradipitant, asking the maker for further studies. Researchers continue to test other prokinetics, but none has yet reached approval for this use.

Sources

Reviewed by Owen Hastings.

• U.S. Food and Drug Administration (fda.gov) and the GIMOTI (metoclopramide nasal spray) prescribing information (dailymed.nlm.nih.gov), for metoclopramide as the only approved gastroparesis drug, the boxed warning on tardive dyskinesia, the twelve-week limit, and the 2020 approval of the nasal spray for adults with acute and recurrent diabetic gastroparesis.
• NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), Treatment for Gastroparesis (niddk.nih.gov), last reviewed January 2018, for the role of prokinetics and antiemetics.
• U.S. Food and Drug Administration, Information about Domperidone and the expanded access program (fda.gov), for domperidone's unapproved status, cardiac risks, eligibility, and the ending of expanded-access supply around September 2025.
• New Developments in Prokinetic Therapy for Gastric Motility Disorders (National Center for Biotechnology Information, National Institutes of Health), for erythromycin's motilin action and the tachyphylaxis that limits it to short-term use.
• For the 2024 decision on tradipitant, the Food and Drug Administration's complete response letter to Vanda Pharmaceuticals dated September 2024.

This page is general health information, not medical advice. Talk to your doctor about your own care. Last reviewed June 2026.